clinical trial · NCT03950232
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Pfizer·phase3·active not recruiting·n = 896
Ulcerative ColitisEtrasimod
brief summary
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 \[NCT03945188\] or APD334-302 \[NCT03996369\] or APD334-210 \[NCT04607837\]).
started
Sep 5, 2019
primary completion
Jun 19, 2029
completion
Jun 19, 2029
last updated
Mar 30, 2026
official title
An Open-Label Extension Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol